# PCSK9 Inhibitor Cuts Heart Risk 31% in Patients Doctors Usually Just Watch - Date: 2026-04-02 - Category: Biotech & Life Sciences The same conference that validated evolocumab left olezarsen with a question mark. The difference is what the drugs actually do to the body — and the answer is shaping the future of preventive cardiology. ---